The FDA this week expanded the use of dupilumab for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis (AD) whose disease is not controlled with topical prescription therapies or when those treatments can't be used.
The FDA this week approved dupilumab (Dupixent) for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis (AD).
The biologic, which came on the US market in 2017, is already approved for AD in patients aged 6 and older, as well as for a number of other type 2 inflammatory atopic diseases. Most patients with AD begin showing symptoms before the age of 5, according to a statement from Sanofi.
Sanofi and Regeneron said they are also pursuing approval for this age group with the European Medicines Agency and in additional countries.
Approval was based on phase 3 data evaluating dupilumab every 4 weeks (200 mg or 300 mg, based on body weight) plus low-potency topical corticosteroids (TCS) or TCS alone (placebo). The trial met the primary and all secondary endpoints.
At 16 weeks, patients who received dupilumab with TCS, compared with TCS alone, achieved the following results:
The safety profile of dupilumab observed through 16 weeks in this young population was similar to the safety profile in patients 6 years and older.
In addition, through 52 weeks, the long-term safety profile of dupilumab in children aged 6 months to 5 years was also similar to what was observed in the pivotal trial and consistent with what was seen in older patients with AD. Hand-foot-and-mouth disease and skin papilloma were, respectively, reported in 5% and 2% of patients on dupilumab aged 6 months to 5 years, and none of these cases led to treatment discontinuation.
Dupilumab is also approved for chronic rhinosinusitis with nasal polyposis AND ASTHMA. Last month, it became the first approved treatment for eosinophilic esophagitis, and the FDA recently accepted it for priority review for the treatment of prurigo nodularis.
Males With Hemophilia A Report Physical, Mental Burdens of Disease Regardless of Severity
April 25th 2024Self-reported data from adult and pediatric males with hemophilia A show that burden of the disease persists regardless of severity, highlighting a need for improved prophylactic treatment.
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More